The Platelia SARS-CoV-2 Total Ab assay screens for total anti-nucleocapsid antibodies IgM, IgA and IgG against coronavirus SARS-CoV-2, the virus associated with COVID-19. The serological assay enables clinicians to identify individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab assay is recommended for use on the Bio-Rad validated, fully-automated EVOLIS Systems or stand-alone systems (IPS/PR4100/PW40), but can also be run on other validated manual or automated platforms. It is one of the first total antibody assays to have obtained U.S. Emergency Use Authorization to test for total antibodies (IgM, IgA, and IgG) in a single assay. In addition, the test has met requirements for applying the CE-mark in Europe.